References
- European Monitoring Centre for Drugs and Drug Addiction EMCDDA 2009 Thematic paper — Understanding the ‘Spice’ phenomenon Luxembourg: Office for Official Publications of the European Communities 2009. ISBN 978-92-9168-411-3. Available at: http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_EMCDDA_Understanding%20the%20%E2%80%98Spice%E2%80%99%20phenomenon_4Update%2020090813.pdf. Accessed May 7th, 2014.
- Alhadi S, Tiwari A, Vohra R, Gerona R, Acharya J, Bilello K. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol 2013; 9:199–206.
- Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use–multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:93–98. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6206a1.htm. Accessed May 7th, 2014
- Bebarta VS, Ramirez S, Varney SM. Complication of spice use in a deployed combat setting-seizure while on duty. Am J Addict 2012; 21:496–497.
- Loschner A, Cihla A, Jalali F, Ghamande S. Diffuse Alveolar Hemorrhage: Add “Greenhouse Effect” to the growing list. Chest 2011; 140:149A–149A. Available at: http://www.journal.publications.chestnet.org/article.aspx?articleID=1088295. Accessed May 7th, 2014.
- Bernson-Leung ME, Leung L, Kumar S. Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Dis Available online 8 October 2013, ISSN 1052-3057, http://www.dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.07.030. Accessed May 7th, 2014.
- Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106:133–145.
- Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58:322–328.
- Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative a-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 2013; 31:223–240.
- Fitzgerald KT, Bronstein AC, Newquist KL. Marijuana poisoning. Top Companion Anim Med 2013; 28:8–12.
- Centers for Disease Control and Prevention (CDC). Notes from the field: Severe illness associated with synthetic cannabinoid use - Brunswick, Georgia, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:939.
- Monte AA, Bronstein AC, Cao DJ, Heard KJ, Hoppe JA, Hoyte CO, et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med 2014; 370:389–390.
- Pant S, Deshmukh A, Dholaria B, Kaur V, Ramavaram S, Ukor M, Teran GA. Spicy seizure. Am J Med Sci 2012; 344:67–68.
- McQuade D, Hudson S, Dargan PI, Wood D. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 2013; 69:373–376.
- EkaJ (20 February 2011). “The night i killed my friends”. Erowid.org. Available at: http://www.erowid.org/experiences/exp.php?ID=89294. Accessed May 7th, 2014.
- Schneir AB, Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 2012; 8:62–64.
- Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 2003; 307:129–137.